PDCD1 and head and neck squamous cell carcinoma: The introduction of immune checkpoint inhibitors (ICIs) has significantly transformed HNSCC therapy, particularly those targeting programmed cell death 1 (PD‐1) and its ligand programmed death‐ligand 1 (PD‐L1).